The impact of expression profiling on prognostic and predictive testing in breast cancer
暂无分享,去创建一个
[1] Ronglai Shen,et al. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. , 2002, The American journal of pathology.
[2] Howard Y. Chang,et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Ioannidis. Microarrays and molecular research: noise discovery? , 2005, The Lancet.
[4] R. Lempicki,et al. Evaluation of gene expression measurements from commercial microarray platforms. , 2003, Nucleic acids research.
[5] Danila Coradini,et al. Biomolecular prognostic factors in breast cancer , 2004, Current opinion in obstetrics & gynecology.
[6] David Grimes,et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[8] S. Wildsmith,et al. Microarrays under the microscope , 2001, Molecular pathology : MP.
[9] S. Lakhani,et al. Molecular evolution of breast cancer , 2005, The Journal of pathology.
[10] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[11] F. Bertucci,et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.
[12] Yudong D. He,et al. Microarrays—the 21st century divining rod? , 2001, Nature Medicine.
[13] Susan G Hilsenbeck,et al. The promise of microarrays in the management and treatment of breast cancer , 2005, Breast Cancer Research.
[14] Stefan Michiels,et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy , 2005, The Lancet.
[15] Wei Wang,et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.
[16] Sridhar Ramaswamy,et al. DNA microarrays in breast cancer: the promise of personalised medicine , 2003, The Lancet.
[17] M. Radmacher,et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. , 2003, Journal of the National Cancer Institute.
[18] M. Ellis,et al. Trawling for genes that predict response to breast cancer adjuvant therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Donna Neuberg,et al. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays , 2004, BMC Genomics.
[20] M. Dowsett,et al. The biology of neoadjuvant chemotherapy for breast cancer. , 2002, Endocrine-related cancer.
[21] G. Ball,et al. High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses , 2005, International journal of cancer.
[22] Edison T Liu,et al. Microarrays and clinical investigations. , 2004, The New England journal of medicine.
[23] Charles Auffray,et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces , 2005, Nucleic acids research.
[24] Y. Baba,et al. Comparison of gene expression measurements from cDNA and 60-mer oligonucleotide microarrays. , 2005, Genomics.
[25] Karl Kornacker,et al. Chipping away at the chip bias: RNA degradation in microarray analysis , 2003, Nature Genetics.
[26] Carole L Yauk,et al. Comprehensive comparison of six microarray technologies. , 2004, Nucleic acids research.
[27] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] A. Ashworth,et al. Molecular profiling of breast cancer: clinical implications , 2004, British Journal of Cancer.
[29] Shinzaburo Noguchi,et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] John Quackenbush,et al. Multiple-laboratory comparison of microarray platforms , 2005, Nature Methods.
[32] M. J. van de Vijver,et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Kenneth H Buetow,et al. Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] Members of the Complex Trait Consortium. Standardizing global gene expression analysis between laboratories and across platforms , 2005 .
[35] Carlos Caldas,et al. Predictive cancer genomics—what do we need? , 2003, The Lancet.
[36] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[37] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[38] Bryan Frank,et al. Independence and reproducibility across microarray platforms , 2005, Nature Methods.
[39] Maurice P H M Jansen,et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] K. Gatter,et al. Ki67 protein: the immaculate deception? , 2002, Histopathology.
[41] M. Stockler,et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.
[42] T. Powles,et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[44] S. Hilsenbeck,et al. Genomic approaches to understanding and treating breast cancer. , 2004, Breast disease.
[45] Soonmyung Paik,et al. Gene expression profiling of breast cancer: a new tumor marker. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Jorge S. Reis-Filho,et al. Molecular Cytogenetic Identification of Subgroups of Grade III Invasive Ductal Breast Carcinomas with Different Clinical Outcomes , 2004, Clinical Cancer Research.
[47] Mike Clarke,et al. Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[48] N. Maughan,et al. An introduction to arrays , 2001, The Journal of pathology.
[49] P. Ravdin,et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Lucila Ohno-Machado,et al. Analysis of matched mRNA measurements from two different microarray technologies , 2002, Bioinform..
[51] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[52] S. Hilsenbeck,et al. Genomic approaches in the management and treatment of breast cancer , 2005, British Journal of Cancer.
[53] William J. Gradishar,et al. Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer , 2004, Clinical Cancer Research.
[54] Syed Mohsin,et al. Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Gavin Sherlock,et al. Of fish and chips , 2005, Nature Methods.
[56] Ash A. Alizadeh,et al. Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.
[57] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] Jane Fridlyand,et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. , 2003, Cancer research.
[59] M. J. van de Vijver,et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome , 2003, British Journal of Cancer.
[60] M Baum,et al. Polychemotherapy for early breast cancer: An overview of the randomised trials , 1998 .
[61] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Kathleen F. Kerr,et al. Standardizing global gene expression analysis between laboratories and across platforms , 2005, Nature Methods.
[63] J. Pierga,et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. , 2003, European journal of cancer.
[64] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. West,et al. Gene expression predictors of breast cancer outcomes , 2003, The Lancet.
[66] R. Tuma. Trial and error: prognostic gene signature study design altered. , 2005, Journal of the National Cancer Institute.
[67] J. Stec,et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Mitch Dowsett,et al. Mechanisms of tamoxifen resistance. , 2004, Endocrine-related cancer.
[69] Eliot Marshall,et al. Getting the Noise Out of Gene Arrays , 2004, Science.
[70] Harold C. Sox,et al. National Institutes of Health Consensus Development Conference Statement: Geriatric Assessment Methods for Clinical Decision‐making , 1988 .
[71] R. Spang,et al. Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[72] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[73] E. Liu. Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[74] A. Ashworth,et al. Microarray and histopathological analysis of tumours: the future and the past? , 2001, Nature Reviews Cancer.
[75] J. Foekens,et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.
[76] J. Brenton,et al. Microarrays and breast cancer clinical studies: forgetting what we have not yet learnt , 2005, Breast Cancer Research.